Bedrijfsoverzicht
Equillium, Inc. is a clinical-stage biotechnology entity dedicated to developing therapeutics for severe autoimmune, inflammatory, and immuno-inflammatory disorders that address unmet medical needs within the United States. The company operates within the broader Healthcare sector, specifically focusing on the specialized industry of Biotechnology, where its primary focus lies in advancing novel drug candidates like Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody. As of the latest available data, the company holds a market capitalization of $113.81M, while specific figures for annual revenue and employee count are not publicly disclosed in the current dataset. This market capitalization indicates that Equillium is a mid-to-small-cap biotechnology firm, a positioning typical for clinical-stage companies that have yet to achieve commercial revenue but possess significant potential value tied to the success of their pipeline. The absence of reported revenue figures suggests that the company is still in the pre-commercialization phase, relying heavily on research and development expenditures rather than sales income to drive its operational model.
Financiële gezondheid
Equillium, Inc. reports a net income of $-22,398,000 over the trailing twelve months, while its EBITDA stands at $-23,518,000, reflecting the significant burn rate characteristic of clinical-stage development. The gap between the reported revenue of N/A and the substantial net loss reveals a cost structure dominated by research, development, and operational overheads rather than cost of goods sold, as the company has not yet generated commercial sales to offset these high fixed costs. Furthermore, the company's free cash flow is $-14,327,250, indicating that the organization is consuming cash reserves to fund its pipeline and operations, which limits immediate financial flexibility but is standard for entities in the early development stages. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that technically results from the lack of commercial revenue rather than an inability to generate profit on sales, effectively rendering these ratios non-informative for evaluating current profitability until commercialization occurs. On the balance sheet side, Equillium holds $30.28M in cash against a debt load of $719,000, resulting in a debt-to-equity ratio of 2.51, which suggests a leveraged capital structure where equity financing has been utilized to offset debt obligations. Despite the reported debt, the current ratio of 10.58 indicates an exceptionally strong short-term liquidity position, as the company possesses ample current assets relative to its current liabilities to cover operational needs. However, the return on equity is -94.0% and the return on assets is -51.4%, metrics that mathematically reflect the company's status as a loss-making entity where equity value is diminished by accumulated deficits rather than generated earnings.
Waarderingsbeoordeling
The valuation of Equillium, Inc. is characterized by a trailing twelve-month P/E ratio of N/A and a forward P/E of -6.86, a discrepancy that implies the market is pricing the stock based on future expectations of profitability that have not yet materialized in historical earnings. The negative forward P/E ratio highlights that the company is currently unprofitable on a forward-looking basis, meaning traditional earnings-based valuation multiples are not applicable at this stage of development. The price-to-book ratio stands at 3.87, indicating that the market values the company at a significant premium of roughly 287% over its book value, a common phenomenon in biotechnology where investors price in the high potential value of intellectual property and clinical pipeline assets rather than current assets. Alternative valuation metrics such as the price-to-sales ratio of N/A and an EV/EBITDA of -3.58 further underscore that the company cannot be valued using traditional commercial benchmarks due to the absence of sales and negative earnings. In terms of trading range, the stock has fluctuated between a 52-week low of $0.27 and a 52-week high of $2.70, providing a wide volatility band for price discovery. The beta of 1.74 indicates that the stock exhibits significantly higher volatility than the broader market, moving with an intensity that is 74% greater than the market average, which poses higher risk and reward characteristics for equity holders.
Growth & Income
Equillium, Inc. reports revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, reflecting the pre-revenue status of the business where historical growth rates cannot be calculated in the traditional sense. Since the company does not generate commercial revenue, there is no distinction between revenue and earnings growth trajectories, as both metrics are currently defined by the absence of sales activity rather than a divergence in growth speed. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flows are reinvested into research and development rather than distributed to shareholders. Consequently, the overall growth and income profile of Equillium, Inc. is entirely dependent on the successful advancement of its clinical pipeline and the eventual achievement of commercial milestones, rather than on current revenue expansion or dividend yields. The absence of dividend payments aligns with the company's lifecycle stage, where capital preservation and pipeline funding take precedence over shareholder income generation.